晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性相关基因多态性的研究

Study on the efficacy and toxicity related gene polymorphism in non-small cell lung cancer patients with gemcitabine chemotherapy

目的对切除修复交叉互补组1（ERCCl）基因多态性与晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性的相关性进行研究。方法选取经病理检查确诊的40例非小细胞肺癌患者作为研究对象，抽取静脉血5m1，提取白细胞DNA，采用PCR-RFLP技术对ERCCl118基因型进行检测，对ERCCl118基因型与晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性之间的关系进行探讨。结果患者年龄、性别及病理学类型、临床分期等因素与治疗效果之间差异均无统计学意义（均P〉0．05）。C／C基因型频率为55．0％（22／40），C／T4-T／T基因型频率为45．0％（18／40），携带C／C基因的患者有效率为45．5％，携带C／T＋T／T基因的患者有效率为22．2％，两者有效率差异无统计学意义（x^2=2．3488，P〉0．05）。结论ERCCl基因多态性与吉西他滨化疗疗效及毒性之间无明显相关性。

Objective To study the efficacy and toxicity related gene polymorphism in non-small cell lung cancer patients with gemcitabine chemotherapy. Methods 40 patients with non-small eel1 lung cancer were chosen in the present study. The leukocyte DNA was extracted from blood samples. ERCC1 118 genotypes were detected by PCR-RFLR The relationship between ERCC1 118 genotype and the chemotherapy efficacy and toxicity of patients received gemcitabine was analyzed. Results The age, gender, pathological type, clinical stage, and other factors had no relation with the treatment effects （ P 〉0.05）. The frequency of C/C genotype was 55.0% （22/40） ,the frequen- cy of C/T ＋ T/T genotype was 45.0% （ 18/40 ）. The effective rate was 45.5 % in patients carrying the C/C gene, The effective rate was 22.2% in patients carrying the C/T ＋ T/T gene, the difference between the two groups was not statistically ＇ sigmficant （ x^ 2 = 2. 3488, P 〉 0.05）. Conclusion The ERCC1 gene polymorphism is not significantly correlated with the efficacy and toxicity of gemcitabine chemotherapy.